FIBROMYALGIA · White paper
Fibromyalgia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About fibromyalgia — and why its trials are hard
Fibromyalgia is a chronic central-sensitization pain disorder characterized by widespread musculoskeletal pain, fatigue, unrefreshing sleep, and cognitive dysfunction ("fibro fog"). It affects an estimated 2 to 4% of the population, with women accounting for roughly 70 to 90% of cases, and commonly overlaps with IBS, migraine, and depression. Diagnosis has shifted from the 1990 ACR tender-point count to symptom-based criteria (Widespread Pain Index and Symptom Severity Scale, refined in 2010/2016 and reflected in ICD-11 code MG30.01). Three drugs carry FDA fibromyalgia indications: pregabalin (2007, the first), duloxetine (2008), and milnacipran (2009); amitriptyline and gabapentin are used off-label. Development is notoriously hard: high placebo response, subjective and fluctuating pain, and heterogeneous patient populations have sunk candidates such as mirogabalin, TNX-102 SL, and IMC-1. Enriched enrollment randomized withdrawal designs, phenotype-based stratification, and multidimensional composite endpoints spanning pain, fatigue, sleep, and function are increasingly used to detect true drug effects.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Pregabalin (Lyrica) | 2007 | First FDA-approved drug for fibromyalgia | Pivotal 14-week trials (e.g., NCT00156933) | Alpha-2-delta calcium-channel modulator; ~50% of patients achieved >=30% pain reduction; improved sleep; dose-dependent adverse effects | |
| Duloxetine (Cymbalta) | 2008 | Fibromyalgia management in adults | Pivotal SNRI trials (e.g., NCT00222995) | SNRI; mean Brief Pain Inventory reduction ~2.4 vs ~1.4 points for placebo (p<0.05); also improved depressive symptoms | |
| Milnacipran (Savella) | 2009 | Fibromyalgia management in adults | Pivotal trials (e.g., NCT00482662) | SNRI with norepinephrine preference; ~57% PGIC global improvement vs ~33% placebo (p<0.01); 100 mg as effective as 200 mg | |
| Gabapentin (Neurontin) | 1993 (off-label for fibromyalgia) | Off-label adjunct for fibromyalgia pain | Investigator study (e.g., NCT00005564) | Alpha-2-delta modulator; ~40% pain-severity reduction vs placebo (p<0.05) with improved sleep in a small trial; not FDA-approved for fibromyalgia | |
| Amitriptyline (Elavil (brand discontinued in U.S.)) | 1961 (off-label for fibromyalgia) | Off-label low-dose tricyclic for pain and sleep | Small comparative studies (e.g., NCT00300767) | Improves pain and sleep (PSQI) in small studies; limited by anticholinergic and sedative effects; not FDA-approved for fibromyalgia |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in fibromyalgia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Mirogabalin — Phase III fibromyalgia program (NCT02146430) | Failed to achieve statistically significant pain reduction vs placebo | Alpha-2-delta ligand; high placebo response and reliance on 'worst daily pain' metric complicated efficacy detection |
| TNX-102 SL (sublingual cyclobenzaprine) — AFFIRM (NCT02436096) | Did not meet primary endpoint of >=30% pain reduction from baseline | Difficulty demonstrating pain benefit over placebo; a later program continued but this pivotal trial failed |
| IMC-1 (famciclovir + celecoxib) — Phase II fibromyalgia (NCT04748705) | Failed to improve pain more than placebo in the overall population | Antiviral/anti-inflammatory hypothesis (targeting herpesvirus reactivation) did not translate into pain efficacy |
Choosing the right endpoint
Primary endpoints that matter in fibromyalgia trials
- Pain reduction — Change on VAS/NRS or Brief Pain Inventory; >=30% and >=50% responder thresholds are standard; subjective and placebo-sensitive
- Patient Global Impression of Change (PGIC) — Global responder measure used across pregabalin, duloxetine, and milnacipran approvals
- Fatigue — Multidimensional Fatigue Inventory and similar tools; hard to isolate given physical, psychological, and social contributors
- Sleep quality — Pittsburgh Sleep Quality Index, actigraphy, or polysomnography; confounded by comorbid sleep apnea
- Cognitive function — Neuropsychological tests (e.g., Trail Making Test) for 'fibro fog'; lacks validated biomarkers
How iNGENū runs fibromyalgia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Fibromyalgia clinical trials — FAQs
Which drugs are actually FDA-approved for fibromyalgia?
Why do so many fibromyalgia drug trials fail?
How is fibromyalgia diagnosed now?
Ready to discuss your fibromyalgia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal